Shortening the Drug Discovery Pipeline for Neglected Diseases
Author Information
Author(s): Cechetto Jonathan, Jeon Hee Kyoung, Jang Jiyeon, Kwon Doyoon, Christophe Thierry, Brodin Priscille, Yang Gyongseon, Neto Jair, Freitas Junior Lucio
Primary Institution: Institut Pasteur Korea
Hypothesis
Can high content screening of small molecules lead to faster and cheaper drug discovery for neglected diseases?
Conclusion
The study found that using high content screening technology can identify novel compounds for neglected diseases more quickly and cost-effectively than traditional methods.
Supporting Evidence
- The study developed a core technology for high content screening of small molecules.
- This technology allows for testing in relevant disease models.
- Active compounds were identified in less time and at lower costs compared to traditional methods.
Takeaway
Scientists found a faster way to discover new medicines for diseases that are often ignored, like Tuberculosis and Chagas, by testing many small molecules at once.
Methodology
The study utilized high content screening technology to test hundreds of thousands of small molecules against relevant disease models.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website